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Abstract
A greater understanding of the biological mechanisms responsible
for  de novo and acquired endocrine resistance has led to the
rational design of clinical trials exploring the benefit of combining
hormonal therapies with novel biological agents in an effort to
enhance the efficacy of ER+ breast cancer treatment. These
studies are increasingly including parallel biological analyses to
elucidate the molecular characteristics of those tumors that are
most likely to respond to specific targeted/endocrine combinations
in an effort to develop a tailored approach to the management of
individual patients. Unfortunately despite encouraging preclinical
data, some of these combinations have yielded disappointing
results in the clinical setting. This article will review the results of
clinical trials of endocrine/biological combinations conducted in
early and advanced breast cancer as well as provide an update on
ongoing studies.
Introduction
Approximately two-thirds of women with breast cancer have
estrogen receptor (ER) positive disease. For several
decades, the selective estrogen modulator tamoxifen was
offered as standard first line therapy for ER+ breast cancer.
In the 1990s, third generation nonsteroidal aromatase
inhibitors (AIs) emerged as a useful alternative for post-meno-
pausal women. However, some do not respond (de novo
resistance) while others may initially experience meaningful
remissions, but eventually progress (acquired resistance). For
post menopausal women, further endocrine manipulation may
offer some benefit. Options include newer steroidal AIs, such
as exemestane, the ER downregulator fulvestrant, or in fact
tamoxifen. Women with advanced breast cancer are living
longer thanks to an increasing number of available effective
chemotherapeutic agents; however, maximizing the benefit of
hormonal therapy remains an important priority. Endocrine
therapy is well tolerated, oral and can offer clinically
meaningful remissions before subsequent relapses that
require intravenous cytotoxic agents. Therefore, finding ways
to abrogate or delay the onset of endocrine resistance has
emerged as an attractive anti-cancer strategy.
Rationale for endocrine/biological
combinations
There is increasing evidence that ER+ breast cancer can
escape normal endocrine responsiveness by upregulating
other signaling pathways involved in cell survival and
proliferation. Overexpression of transmembrane peptide
growth factor receptors, such as the epidermal growth factor
receptor (EGFR) or the human epidermal receptor 2 (HER2)
has been associated with poor prognosis and resistance to
hormonal therapy [1,2]. Similarly, activation of downstream
intracellular signaling via the ras-raf-mitogenic-activated
protein kinase (MAPK) pathway and the phosphatidylinositol
3-kinase (PI3K)/Akt pathway has been implicated in
endocrine resistance [3-5]. These pathways activate down-
stream effectors, which phosphorylate ERα and its co-
activators (for example, AIB1), leading to ligand-independent
transcription of ER responsive genes [6,7]. For example, both
MAPK and Akt have been shown to directly phosphorylate
ER, at Ser118 and Ser167, respectively [8,9]. This cross-talk
between ER and these alternative signaling pathways may
allow cells to escape the antiproliferative effects of endocrine
therapy [10,11]. Several biological agents, such as
monoclonal antibodies and tyrosine kinase inhibitors, have
been developed to target key proteins along these signal
transduction cascades.
Importantly, even following the development of endocrine
resistance, ER signaling continues to play an important role in
the proliferation of breast cancer. Biopsies of tumors from
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breast cancer patients who have relapsed on an anti-
estrogen show a functional ER [12], while women who have
become refractory to tamoxifen can respond to further
endocrine manipulation with an AI, or fulvestrant [13]. In vitro
studies with long-term estrogen-deprived cells (LTED) have
shown that breast cancer cells adapt to endocrine
deprivation by becoming hypersensitive to estradiol doses as
low as 10-12 M [14,15]. Taken together, these data suggest
that ER-mediated signaling remains relevant even in the
setting of endocrine resistance. Given the evidence that the
ER remains functional and can interact with growth factor
signaling pathways, there is a strong rationale for combining
novel signal transduction inhibitors with endocrine therapy
rather than using them on their own.
Another strategy involves combining hormonal therapy with
angiogenesis inhibitors. Angiogenesis, or the formation of
new blood vessels, is critical to tumor growth and is
principally mediated via tumoral secretion of vascular
endothelial growth factor (VEGF). Furthermore, cell line
models suggest that estrogen may have pro-angiogenic
effects by increasing VEGF gene transcription [16], while
increased VEGF receptor signaling may promote endocrine
resistance [17]. Co-targeting the tumor with endocrine
therapy as well as its associated vasculature using anti-angio-
genic agents may provide a more effective anticancer therapy.
A greater understanding of the biological mechanisms
responsible for the development of endocrine resistance has
led to the rational design of clinical trials exploring the benefit
of combining hormonal therapies with novel targeted agents
in an effort to enhance the efficacy of ER+ breast cancer
treatment. These studies are increasingly including parallel
biological analyses to elucidate the molecular characteristics
of those tumors that are most likely to respond to specific
targeted/endocrine combinations in an effort to develop a
tailored approach to the management of individual patients.
This article will review the results of clinical trials of
endocrine/biological combinations conducted in early and
advanced breast cancer as well as provide an update on
ongoing studies.
Combination with EGFR inhibitors
Gefitinib and erlotinib are small molecule tyrosine kinase
inhibitors of the ATP binding site of EGFR and have been
shown to delay the development of tamoxifen resistance in
vitro [18]. Three studies exploring the benefit of combining
gefitinib with the aromatase inhibitor anastrazole have been
reported (Table 1).
A phase II trial of the combination in women with metastatic
breast cancer who had previously failed hormonal therapy
showed no clinical activity [19]. In early breast cancer, a
randomized neoadjuvant trial of anastrazole alone or in
combination with gefitinib given for three months prior to
surgery was also negative. In fact, although not statistically
significant, there was a trend favoring the endocrine alone
arm both in terms of objective response rate (RR = 61%
versus 48%, p = 0.067) and antiproliferative effects as
measured by reduction in Ki67 [20]. Further molecular
studies of tumor specimens obtained pre- and post-treatment
are underway, which may help explain these findings.
In contrast, a preoperative trial by Polychronis and colleagues
[21] comparing single-agent gefitinib to gefitinib combined
with anastrozole for four to six weeks prior to surgery
demonstrated that both treatment arms effectively reduced
the size of breast tumors and levels of ER phosphorylation,
with the combination treatment outperforming gefitinib alone
in terms of reduction in tumor proliferation rate as measured
by Ki67 [19]. However, the inclusion criteria for these studies
differed. The first two studies showing no benefit to the
combination enrolled an unselected population of post-
menopausal women with hormone receptor + breast cancer
[19,20], while Polychronis and colleagues’ study enrolled
only patients who were both ER and EGFR+, thus including
only patients expressing the known target for gefitinib, which
could explain their positive results [21]. It is worth
emphasizing that the reported rates for ER/EGFR co-
expression in breast cancer vary quite dramatically among
studies (range 5% to 50%) [21-23] and may be attributable
to variability in age of archived tissue, fixation techniques and
EGFR antibody specificity [24]. However, most studies do
support that EGFR and ER expression are inversely related,
with twice the rate of EGFR positivity among ER- compared
to ER+ tumors [23]. In addition, whether EGFR expression
will actually prove to be a valid predictor of response to
erlotinib or gefitinib in breast cancer is unclear. Lessons
learned from lung cancer suggest that activating mutations in
the tyrosine kinase domain or gene amplification may more
reliably predict the subset of patients likely to benefit [25,26].
Interim results of a phase II study of erlotinib and letrozole in
hormone sensitive metastatic breast cancer were recently
reported. The combination was well tolerated and 11 of the
first 20 patients experienced clinical benefit rate (CR = 1,
partial response (PR) = 4, stable disease (SD) >6 months =
6) [27]. The trial is ongoing and biomarker analyses are
underway to assess whether EGFR, HER2 or ER
phophorylation at Ser118 may predict for benefit from this
combination. Planned accrual is 150 patients and the
investigators feel that if a clinical benefit of 65% is achieved,
a phase III randomized trial would be justified.
Despite these mixed results, a significant number of trials
remain ongoing, investigating the combination of gefitinib
with AIs or other endocrine therapies such as tamoxifen or
the ER downregulator fulvestrant (Table 2). One small study
is investigating whether gefitinib may restore endocrine
sensitivity by randomizing women with tamoxifen resistant
disease to gefitinib alone or in combination with tamoxifen.
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Table 1
Combinations of endocrine therapies with biological agents: completed trials in ER+ and/or PgR+ breast cancer 
Clinical setting Trial phase Intervention Clinical endpoints Biological correlates Ref.
Combination with gefitinib
MBC: hormone-refractory II (N = 15) ANA + GEF PR = 0  NA [19]
SD = 0
Neoadjuvant PBC II RCT (N = 188) ANA versus ANA +  ORR = 61% versus  Reduction in Ki67 =  [20]
GEF for 16 weeks 48%, p = 0.067  83.6% versus 77.4%, p = 0.164
Preoperative PBC:  II RT (N = 56) GEF versus GEF +  ORR = 50% versus  Reduction in Ki67 =  [21]
EGFR+ only ANA for 4-6 weeks 54% 92.4% versus 98%, p = 0.005 
Reduction in pER, pMAPK and 
pEGFR similar in both groups
Combination with trastuzumab
HER2+ MBC (note: all  II (N = 33) TRAS + LET PR = 26%  NA [29]
patients were TRAS and  SD = 26%
AI naïve, 18% were 
IHC2+/FISH-)
HER2 MBC (all patients  III RCT (N = 207) ANA versus ANA +  PFS = 2.4 months  NA [31]
were IHC 3+ or FISH+) TRAS versus 4.8 months, 
p = 0.0016 
OS = 23.9 months 
versus 28.5 months, 
p = 0.325 
Among 147 evaluable 
patients: ORR = 6.8% 
versus 20.3%, p = 0.018
Combination with lapatinib
MBC: included other  I (N = 17) LAP + LET 4 SD including 1 breast  NA [36]
hormone sensitive  cancer
advanced cancers
Combination with farnesyltransferase inhibitors: tipifarnib
MBC: hormone resistant  I (N = 12) TAM + TIP PR = 2/12  NA [42]
SD >6 months = 1/12
MBC: tamoxifen resistant I (N = 20) TAM + TIP PR = 1/20  NA [41]
SD >4 months = 6/20 
SD >6 months = 4/20
MBC: tamoxifen resistant II RCT (N = 120) LET versus  PR = 38% versus 30%  NA [43]
LET + TIP SD = 38% versus 39%
Combination with mTOR inhibitors: everolimus and temsirolimus
MBC: stable or slowly  Ib (N = 9) LET + EVE 1, 5 or  No grade 3-4 toxicities  NA [50]
progressing on letrozole.  10 mg daily at 5 mg (6 patients) or 
10 mg (3 patients)
MBC II (N = 92) LET versus  ORR = 45% versus  NA [51]
LET+TEM 10 mg  33% versus 40% 
daily versus  PFS = 11.6 months 
LET+TEM 30 mg  versus 11.5 months 
intermittent versus 13.2 months
MBC III RCT (N = 992) LET versus  ORR = 24% versus 24% NA [52]
LET + TEM intermittent SD = 19% versus 16% 
PFS = 9.2 months versus 
9.2 months 
Combination with angiogenesis inhibitors: bevacizumab
MBC II (N = 25) LET + BEV PR = 2/25  NA [57]
SD >6 months = 13/25 
SD <6 months = 4/25 
PD = 6/25
AI, aromatase inhibitor; ANA, anastrozole; BEV, bevacizumab; ER, estrogen receptor; EVE, everolimus; FISH, fluorescent in situ hybridization; GEF,
gefitinib; HER, human epidermal receptor; IHN, immunohistochemistry; LAP, lapatinib; LET, letrozole; MBC, metastatic breast cancer; mTOR,
mammalian target of rapamycin; NA, none available; ORR, objective response rate (PR + clinical benefit rate); OS, overall survival; PBC, primary
breast cancer; PD, progressive disease; pEGFR, phosphorylated endothelial growth factor receptor; pER, phosphorylated ER; PFS, progression
free survival; PgR, progesterone; pMAPK, phosphorylated mitinogen activated protein kinase; PR, partial response; RCT, randomized controlled
trial; RT, randomized trial; SD, stable disease; TAM, tamoxifen; TEM, temsirolimus; TIP, tipifarnib; TRAS, trastuzumab.Breast Cancer Research    Vol 9 No 5 Leary et al.
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Table 2
Endocrine/biological combinations: ongoing or recently closed trials in ER and/or PgR+ breast cancer
Clinical setting Trial phase Intervention N Biological endpoints NCT protocol #
With EGFR inhibitors: gefitinib (GEF) or erlotinib (ERL)
Neoadjuvant PBC:  II GEF × 2 weeks followed  45 Tumor biomarker analysis at weeks 1,  00206492
(HER2+ only) by GEF+TAM 2, 6 and surgery
Neoadjuvant PBC II ANA + FUL + GEF 40 Tumor biomarker analysis pre- and  00206414
post-treatment
MBC II RCT TAM +/-GEF 274 Correlate RR to HER2/A1B1 status  00069290
and other biomarker studies
MBC II RCT ANA+/- GEF 174 biomarker study 00077025
MBC II RCT ANA +/- GEF 108 None specified 00066378
MBC II FUL+GEF 60 None specified 00234403
MBC II RT ANA+GEF vs FUL+GEF 148 Identify biologic predictors 00057941
MBC II LET +ERL 150 Correlation of EGFR, HER2 and  00179296
pERSer118 to benefit
MBC: TAM resistant II RT GEF+/-TAM 46 Correlate early changes on PET and  00080743
in plasma DNA to response
With Trastuzumab
HER2+ MBC: AI-resistant II TRAS monotherapy until  40 Correlate benefit with HER2 ECD at  00238290
PD followed by TRAS + LET baseline and after treatment
HER2+ MBC III RCT ANA+/- TRAS NA None specified 00022672
HER2+ MBC: TRAS-naive IV LET+ TRAS 370 None specified 00171847
With Lapatinib (LAP)
MBC: TAM-resistant II LAP+TAM 41 None specified 00118157
MBC III RCT LET +/- LAP 128 Biomarker and genetic variant analysis 00073528
MBC: HER2 1+, 2+, 3+  III RCT FUL+/-LAP 324 None specified 00390455
or FISH+
With FTIs: lonafarnib (LON) and tipifarnib (TIP)
MBC II RCT ANA +/-LON 124 None specified 00081510
MBC II RCT ANA +/- LON 110 None specified 00098904
MBC II RCT LET+ TIP (continuous)  108 None specified 00061971
vs LET + TIP (intermittent) 
vs LET
MBC II TAM + TIP 27-40 Note: efficacy stratified according to  00052728
benefit from prior hormone tx
MBC II FUL + TIP 45 Efficacy and toxicity 00082810
With mTOR inhibitors: everolimus (EVE) and temsirolimus (TEM)
Neoadjuvant PBC II RCT LET+/-EVE 255 None specified 00107016
MBC II RCT LET+/-TEM 90 None specified 00061971
With angiogenesis inhibitors: Bevacizumab (BEV), vatalanib (VAT) 
Neoadjuvant PBC II LET+BEV 25 None specified 00161291
MBC: With acquired II BEV will be added to  30 Correlate metabolic response by PET 
endocrine resistance* current endocrine therapy to clinical benefit 00240071
MBC II BEV+LET 42 Tumor biomarker analysis 00187694
Correlate serial endothelial and 
epithelial cell measurements to 
response and markers of angiogenesis
MBC II BEV+ANA or FUL 80 None specified 00405938
MBC II VAT+LET 32 None specified 00263198
With multitargeted TKIs: sorafenib (SOR), imatinib (IMA)
MBC: AI-resistant I/II ANA +SOR 50 Assess changes in Raf and VEGF  00217399
signalling in tumor and stroma
MBC: PDGFR or c-kit + only II LET+IMA 45 Serum measurements of VEGF, bFGF,  00338728
IL8, PDGF, TNF, E-selectin
Combination with HDAC inhibitor SAHA
MBC II TAM+SAHA 42 Pre-and post treatment ER expression  00365599
and histone acetylation
*Acquired endocrine resistance defined as: actively progressing on current endocrine therapy AND history of prior response to current endocrine
therapy (i.e. CR, PR or SD > 6 months). PBC, primary breast cancer; MBC, metastatic breast cancer; RCT, randomized controlled trial; RT,
randomized trial; PR, partial response; SD, stable disease; ORR, objective response rate (PR+CR); ANA, anastrozole; FUL, fulvestrant; LET,
letrozole; PFS, progression free survival; OS, overall survival; TAM, tamoxifen. Source: www.cancer.gov/clinicaltrials.based on EGFR status, while one neoadjuvant trial of
tamoxifen plus gefitinib is enrolling only HER2+/ER+ patients
based on preclinical evidence that EFGR inhibitors may
reduce HER2 signaling by interfering with EGFR-HER2
heterodimerization [28], and this study includes tumor
biomarker analysis at baseline, weeks 2, 6 and surgery.
Combinations with trastuzumab
Trastuzumab, the monoclonal antibody against HER2,
reduces downstream MAPK/ERK1/2 signaling, and at least
partially reverses tamoxifen resistance in vitro [2]. It is a
common misconception that most HER2+ tumors are ER-,
and this is illustrated by 50% of patients enrolled in the
recent adjuvant trastuzumab trials being either ER+ or PgR+.
HER2+/ER/PgR+ breast cancer patients therefore represent
an important group with potential de novo endocrine
resistance.
A phase II clinical trial of letrozole and trastuzumab in patients
with ER+/HER2+ metastatic breast cancer revealed that the
combination was well tolerated and had a clinical benefit rate
(PR + SD) of 50%, with durable objective tumor responses
(PR) for greater than 1 year in 25% of the patients [29]
(Table 1). Inclusion criteria included no prior exposure to
trastuzumab, AI naive and no more than one prior chemo-
therapy for metastatic disease. It is worth noting that the
same clinical benefit rate of 50% is reported with first-line
single agent trastuzumab [30], making it difficult to draw
robust conclusions regarding the added benefit of letrozole.
Furthermore, as highlighted by the investigators, this means
that almost half of these ER+/HER2+ patients demonstrated
de novo resistance to dual ER/HER2 inhibition, suggesting
that in a subgroup of patients other targets may be relevant.
The randomized phase III TANDEM trial in 207 patients with
ER+/HER2+ metastatic breast cancer recently reported a
doubling of progression free survival (PFS) with the addition
of trastuzumab over anastrozole alone (4.8 months versus
2.4 months,  p = 0.0016) [31]. There was no significant
difference in overall survival; however, 70% of patients in the
anastrozole alone arm crossed over to the combination upon
progression. Interestingly, the objective response rate to the
combination was again only 23%, similar to that observed
with first line single agent trastuzumab. Also, the response
rate to single agent anastrozole was surprisingly poor at only
6.8%, although these patients were all ER+/HER2+. A three
arm randomized trial of trastuzumab, an AI or the combination
is required to confirm whether the combination actually offers
an additive benefit.
There remain three ongoing studies looking at trastuzumab in
combination with AIs (Table 2). One of them has an
interesting design - it is enrolling women with trastuzumab
naïve HER2+/ER+ metastatic breast cancer who have
progressed after an AI and offering trastuzumab monotherapy
until progression, followed by trastuzumab/letrozole combina-
tion. This study will test the in vitro models showing that
growth factor targeted therapy, such as trastuzumab, can
restore endocrine sensitivity.
Combination with dual EGFR/HER2 inhibitor
lapatinib
Lapatinib is an oral tyrosine kinase inhibitor of both EGFR and
HER2. As a dual inhibitor it may have the potential for greater
anti-tumor effect than strategies targeting a single receptor.
Indeed, EGFR and HER2 belong to a family of four human
EGFRs. These receptors can become aberrantly activated
due to significant receptor overexpression, mutations, or
ligand-dependent receptor dimerization [32,33]. HER2 does
not have a known ligand but represents the preferred
dimerization partner for the other members. A dual
EGFR/HER2 inhibitor may, therefore, have the potential to
target a greater number of tyrosine kinase homo- or hetero-
dimer complexes. In vitro data have demonstrated that
estrogen deprivation significantly enhances the anti-
proliferative effects of lapatinib in HER2 amplified breast
cancer cell lines [34,35], which provides the rationale for
investigating the possible additive or synergistic effects of
combining lapatinib with aromatase inhibitors.
A phase I study has shown that the combination with
letrozole is well tolerated, with toxicities consisting mainly of
grade 1-2 diarrhea, nausea, rash and fatigue [36]. Clinical
data to date show that HER2 overexpression is a strong
predictor of response; whether it is in fact an obligate
requirement remains to be determined. Three studies of
lapatinib in combination with endocrine treatment are
ongoing - two are recruiting patients with ER+ disease
regardless of EGFR or HER2 status. The first is a small phase
II trial of lapatinib and tamoxifen in tamoxifen resistant
advanced breast cancer. The design of this study is
supported by preclinical evidence that lapatinib can
significantly enhance sensitivity to tamoxifen in cell lines with
acquired tamoxifen resistance and adaptive HER2
upregulation [35,37]. The second is a large phase III trial
randomizing patients with metastatic ER+ breast cancer to
letrozole +/- lapatinib. Again, patients are selected regardless
of their EGFR/HER2 status, but will be stratified according to
the time interval since adjuvant tamoxifen (>6 or <6 months).
This study may offer important insight into the subgroups of
patients most likely to benefit from a lapatinib-endocrine
combination, such as known HER2+/ER+ breast cancer with
potential de novo endocrine resistance, or tumors that might
develop acquired resistance to letrozole during treatment due
to adaptive HER2 upregulation. To identify the latter, all
patients have serum taken at baseline entry for assessment of
circulating extracellular domain HER2, which has been
reported to be a predictor of poorer outcome with endocrine
therapy, with seroconversion occurring during endocrine
therapy in up to 25% of cases [38]. Finally, a CALGB trial is
randomizing women with advanced ER+ breast cancer and
some degree of HER2 expression (for example, fluorescent in
Available online http://breast-cancer-research.com/content/9/5/112
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1+, 2+, or 3+) to fulvestrant alone or in combination with
lapatinib.
Combination with farnesyltransferase
inhibitors
Interfering with the downstream effectors of growth factor
receptors has emerged as another effective anti-tumor
strategy. Ras proteins are membrane bound GTP-binding
proteins that are frequently aberrantly expressed in breast
cancer [39]. They act as mitogenic switches between growth
factor receptors and downstream intracellular signaling via
Raf/MAPK. These proteins require post-translational transfer
of a hydrophobic farnesyl moiety to bind to the inner plasma
membrane. This reaction is catalyzed by the farnesyl-
transferase enzyme. Farnesyltransferase inhibitors (FTIs),
such as tipifarnib and lonafarnib, were developed in an effort
to interrupt this pathway by inhibiting farnesylation, the first
step in Ras activation.
Based on encouraging results in cell line and tumor xenograft
models [5,40], trials have been conducted in combination
with tamoxifen or AIs (Table 1). Interim results on a small
study of tamoxifen plus tipifarnib in metastatic tamoxifen
resistant breast cancer suggested some activity with 1 PR
and 4 SD >6 months among the first 20 patients analyzed
[41]. A similar phase I trial reported a CR of 25% with
tamoxifen and tipifarnib in a heavily pretreated hormone
resistant patient population, further supporting preclinical
data that FTIs may modulate endocrine responsiveness [42].
Unfortunately, a larger randomized phase II study of letrozole
+/- tipifarnib was disappointing. Among 120 women with
tamoxifen resistant disease, the addition of the FTI failed to
improve objective response rate (PR = 38% to letrozole
alone versus PR = 30% for the combination) [43]. A number
of theories could explain these findings. The targets for FTIs
are still poorly understood; up to 30 proteins that require
farnesylation have been identified to date and their roles in
cellular growth and survival are unknown [44]. Furthermore,
Ras proteins are not only farnesylated, but can also be
modified, or prenylated, by the addition of a geranylgeranyl
moiety [44]. Therefore, compensatory geranylgeranylation
can offer a way to escape from the inhibitory effects of an FTI.
Equally, the benefit of FTIs may be to enhance stable disease
and time to disease progression; as such, a much larger
randomized phase III trial in over 600 patients may have been
needed to demonstrate a significant clinical effect. This
phase II study may have been substantially underpowered.
Other randomized trials in combination with an aromatase
inhibitor as first or second line treatment are ongoing.
Combination with inhibitors of the
mammalian target of rapamycin
The PI3K/Akt/mammalian target of rapamycin (mTOR)
pathway is activated by a number of growth factors, including
insulin, insulin-like growth factor I, basic fibroblast growth
factor, EGF and VEGF. Inhibiting this key effector of multiple
pro-survival signals has, therefore, emerged as a viable
therapy. Mutations in the catalytic domain of PI3K have been
identified in 20% to 25% of breast cancers [45,46]. A further
15% to 35% of breast cancer patients demonstrate reduced
expression of PTEN (phosphatase and tensin homolog
deleted on chromosome ten), an endogenous inhibitor of the
PI3K/Akt pathway [47]. PTEN loss has been associated with
poor prognosis in patients with ER+ breast cancer treated
with tamoxifen [48]. Not surprisingly, gain in function
mutations in PI3K and loss of PTEN are mutually exclusive.
Taken together, this would suggest that half of breast
cancers have an upregulated PI3K/Akt pathway due to a
constitutively active signal downstream of membrane
receptors. This subset of cancers may be resistant to
strategies targeting upstream growth factor receptors, but
particularly sensitive to PI3K or mTOR inhibition. In addition,
preclinical studies have demonstrated that the combination of
letrozole with an mTOR inhibitor results in synergistic growth
inhibition and apoptosis in ER+ breast cancer cell models
[49].
While PI3K inhibitors are still in the early stages of
development, mTOR inhibitors are currently being tested in
combination with endocrine therapies. A small dose finding
phase Ib study of letrozole and the mTOR inhibitor everolimus
suggested that the combination is well tolerated [50]. A
phase II study of letrozole alone or in combination with
another inhibitor, temsirolimus 10 mg daily or 30 mg
intermittently (daily for 5 days every 2 weeks), has also been
reported [51]. Preliminary results suggested a modest benefit
to the combination with intermittent temsirolimus in terms of
median PFS (13.2 months versus 11.6 months) and survival
(90% versus 76%), although the response rate was not
significantly different (40% versus 45%). Notably, the
combination was associated with significant toxicities not
observed in the letrozole alone arm: grade 1-4 diarrhea (43%)
and mucositis (43%) and grade 3-4 hyperglycemia (20%).
Unfortunately, a resulting large phase III randomized trial of
letrozole +/- temsirolimus (intermittent schedule) was
terminated early after an interim analysis demonstrated a lack
of benefit for the combination. Results among the first 992
patients showed no difference in objective response rates or
PFS; the combination was better tolerated than reported in
the original phase II, with less than 5% grade 3-5 toxicities,
including only 4% hyperglycemia [52]. Ongoing trials include
a neoadjuvant trial of letrozole +/- everolimus where
molecular markers of mTOR inhibition will be correlated with
tumor response. In vitro data suggest that mTOR inhibition
can lead to a paradoxical increase in Akt activation, via a
release of negative feedback on upstream signaling through
insulin-like growth factor-1 receptor (IGF1R) [53], or direct
activation by the rapamycin-insensitive mTOR-rictor complex
[54]. In the setting of hormone receptor positive breast
cancer, mTOR inhibition and the resulting increase in Akt
Breast Cancer Research    Vol 9 No 5 Leary et al.
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negate the effects of aromatase inhibition, thus limiting the
therapeutic benefit of this combination.
Combination with angiogenesis inhibitors
Targeting the vascular supply in addition to the cancer cell
itself may be particularly useful against tumors with acquired
resistance to traditional therapies. The proof of principle for
this approach has been demonstrated by the successful use
of a monoclonal antibody against VEGF (bevacizumab) in
combination with chemotherapy in the treatment of colon and
breast cancers [55,56]. A phase II study of letrozole and
bevacizumab reported preliminary results [57]. There were 28
patients evaluable for toxicity. Grade 2-3 side effects
consistent with the known safety profile of bevacizumab
included hypertension (9 patients), headache (5 patients) and
proteinuria (4 patients); there were no grade 4 toxicities. Of
the 25 patients assessable for objective responses, there
was evidence for modest antitumor activity (PR = 2 patients,
SD >6 months = 13, SD <6 months = 4 and progressive
disease (PD) = 6). Efficacy may have been limited by the fact
that previous aromatase inhibitor use without evidence of
progression was allowed, and the majority of enrolled
patients actually had prior exposure to letrozole or
anastrazole. A phase II study of bevacizumab and letrozole in
metastatic breast cancer is currently enrolling patients. This
trial will correlate tumor and serum molecular markers,
including serial circulating endothelial and tumor cell
measurements, to response.
The question of whether VEGF inhibition can reverse
acquired endocrine resistance is currently being investigated
in a phase II trial. Bevacizumab is added to current endocrine
therapy in women actively progressing on hormonal therapy,
after a prior history of objective response or SD >6 months.
A number of other studies are planned. The CALGB (Cancer
and Leukemia Group B) trial 40503 will randomize women
with metastatic ER+ breast cancer to first line treatment with
letrozole or tamoxifen +/- bevacizumab and will allow for
crossover to combination for women progressing in the
endocrine therapy alone arm. This design is unique in that it
takes into account that women are now receiving a variety of
endocrine agents in the adjuvant setting and that there is an
increasing need to redefine the role of tamoxifen alone or in
combination with targeted agents after relapse on adjuvant
AIs. The North Central Cancer Treatment Group (NCCTG) is
about to open a trial of first line fulvestrant and bevacizumab
in women previously treated with an AI.
Another way to target angiogenesis is using selective
inhibitors of the VEGF receptor kinase, such as Vatalanib
(PTK787/ZK). This oral small molecule has shown clinical
activity in phase I trials, with toxicities consisting mainly of
grade 1 or 2 nausea, vomiting, fatique and dizziness [58] and
is currently being investigated in combination with letrozole
as first-line treatment for advanced breast cancer.
Combinations with multitargeted tyrosine
inhibitors
While most of the biological agents discussed so far aim to
target a single receptor or a single family of related kinases,
we are also witnessing the development of multitargeted
kinase inhibitors. In theory, such an approach may abrogate
or delay resistance by disrupting multiple pathways at once.
A number of small molecule inhibitors of multiple kinases
have entered the clinic. Sorafanib has the potential for both
antiangiogenic effects, via inhibition of VEGFR and platelet-
derived growth factor receptor (PDGFR), as well as
antiproliferative effects, via Raf kinase inhibition. A trial of
sorafenib and anastrazole is ongoing and plans to investigate
pre- and post-treatment changes in RAF-MAPK and VEGF
signaling pathways in tumor and stroma.
Imatinib was one of the first successful targeted therapies,
initially developed as a specific inhibitor of the bcr-abl kinase
aberrantly expressed in chronic myelogenous leukemia.
However, it is now evident that this agent has more than one
target, including c-kit and PDGFR, which have been shown to
be overexpressed in a subset of breast cancers and
associated with poor prognosis [59]. A phase II study of
letrozole and imatinib showed that the combination was well
tolerated, with grade 3 toxicities consisting of nausea,
vomiting and dyspepsia. No efficacy data are available and 9
of the first 15 patients were c-kit and or PDGFR positive [60].
A trial is recruiting patients with PDGFR or c-kit over-
expression to letrozole plus imatinib and will include a parallel
biomarker analysis.
Combination with modulators of transcription
Another possible mechanism of hormone resistance involves
ER post-translational silencing via hypermethylation or
histone deacetylation of the ER promoter. Both of these
epigenetic modifications can repress ER transcription and
have been implicated in endocrine resistance [61].
Importantly, this process has been shown to be reversible in
vitro, where treatment of ER negative breast cancer cells with
demethylating agents reactivated functional ER expression
[62,63]. Histone deacetylation (HDAC) inhibitors are
beginning to enter the clinic. Acetylation or the inhibition of
deacetylation stabilizes the interaction of nucleosomes and
DNA, thereby facilitating transcription of silenced genes [64].
Suberoylanilide hydroxamic acid (SAHA) is an oral HDAC
inhibitor that has demonstrated some anti-tumor activity in the
phase I setting; dose limiting toxicities included dehydration,
anorexia and diarrhea [65].
A study of SAHA in combination with tamoxifen in women
previously treated with an AI or tamoxifen is ongoing, the
biological rationale for this study being that the HDAC
inhibitor may restore endocrine sensitivity by restoring ER
expression. Where feasible, serial biopsies will be obtained to
assess for treatment induced changes in acetylation and ER
expression.
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A huge number of endocrine/targeted combinations are
currently being tested in the clinic and may offer true promise
for the future of women with ER+ breast cancer. However,
careful consideration needs to be given both for cross-
competing or additive toxicities, and in designing appropriate
clinical trials that have the ability to clearly demonstrate any
added benefit for these novel (and expensive) therapies.
Subtle deviations from the conventional trial design are
required to assess the efficacy of these combinations. Given
a relatively favorable toxicity profile, early dose finding studies
of endocrine therapy with novel agents should aim to identify
the biologically effective dose as defined by demonstration of
target inhibition rather than the maximum tolerated dose. As
these agents may have more of a cytostatic than cytotoxic
effect, alternative endpoints to objective response may be
appropriate. Clinical benefit and time to progression are
increasingly being used as primary endpoints, while more
studies are allowing the inclusion of patients with non-
measurable sites of disease. Despite a strong scientific
rationale and encouraging results in preclinical studies, some
combinations have proven disappointing in the clinical
setting. Specific combinations are unlikely to be effective in
an unselected population. Taking these combinations forward
will require identifying the subset of tumors that demonstrate
activation and dependence on the pathways targeted by
these novel drugs. An effort to include biomarker studies in
future trials remains an imperative. Given the small but
statistically significant improvement in disease free survival
(DFS) of aromatase inhibitors over tamoxifen, it is not
surprising that most ongoing trials are focusing on combining
biological agents with AIs. However, as more women are
receiving an AI upfront in the adjuvant setting, the role of
second line tamoxifen alone or in combination with novel
therapies remains to be determined, and it is encouraging,
therefore, that studies are starting to include tamoxifen.
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